GLPBio

Ursodiol

Catalog No.: GC13363Purity:>99.00%Synonyms: NSC 683769, UDCA, Ursodiol
COASDSData Sheet
Ursodiol (Ursodeoxycholat) ist eine sekundÄre GallensÄure, die bei der Umwandlung von (Cheno)desoxycholsÄure durch Darmbakterien entsteht und als SchlÜsselregulator fÜr die IntegritÄt der Darmbarriere fungiert und fÜr den Fettstoffwechsel unerlÄsslich ist.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.

Ursodiol
Cas No.: 128-13-2
10mM (in 1mL DMSO)In Stock
$35.00
1
500mgIn Stock
$25.00
1
1gIn Stock
$28.00
1
5gIn Stock
$65.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

Zitate (Citations)

1 publicationsPublikationen von Forschern, die dieses Produkt verwenden

Beschreibung (Description)

Ursodiol (UDCA) is a secondary bile acid derived from the 7α/β isomerization of the primary bile acid chenodeoxycholic acid (CDCA) by microorganisms. Ursodiol can be used in the study of various liver diseases and gastrointestinal diseases. Ursodiol has cytoprotective, anti-apoptotic, membrane-stabilizing, antioxidant and immunomodulatory effects[1-3].

Ursodiol can inhibit the viability of HepG2 and BEL7402 cells with IC50 of 0.92 mmol/L and 0.86 mmol/L, respectively, but Ursodiol has no effect on the viability of normal hepatocytes L-02. After Ursodiol (1.0 mmol/L) treatment, the apoptosis rate of HepG2 and BEL7402 cells was significantly increased in a concentration-dependent manner, whereas the apoptosis rate of L-02 cells did not change significantly.Ursodiol inhibits Bcl-2 expression and promotes Bax expression [2].

Mice treated with low and high doses (50 and 450 mg/kg/day) of Ursodiol showed significant weight loss, whereas 150 mg/kg/day had no significant effect on mouse body weight. After 21 days of ursodiol treatment, the microbial community structure and bile acid pool in the ileum and cecum contents and feces of mice were significantly changed compared with those before treatment. Ursodeoxycholic acid (UDCA), Tauroursodeoxycholic acid (TUDCA), Glycoursodeoxycholic acid (GUDCA) and Lithocholic acid (LCA) levels were significantly elevated in the ileum of mice treated with Ursodiol 450 mg/kg[1]. Ursodiol treatment at 416 mg/kg reduces SARS-CoV-2 transmission in a Syrian golden hamster SARS-CoV-2 infection model[4].

References:
[1]Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021 Feb 18;16(2):e0246161.
[2] Liu H, Qin CY, Han GQ, Xu HW, Meng M, Yang Z. Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J Gastroenterol. 2007 Mar 21;13(11):1652-8.
[3] Kumar D, Tandon RK. Use of ursodeoxycholic acid in liver diseases. J Gastroenterol Hepatol. 2001 Jan;16(1):3-14.
[4] Brevini T, Maes M, Webb G J, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2[J]. Nature, 2023, 615(7950): 134-142.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

Hepatoma cells BEL7402 and HepG2 and normal liver cells L-02

Preparation Method

Hepatoma cells BEL7402 and HepG2 and normal liver cells L-02 were treated with Ursodiol at concentrations ranging from 0.05mmol/L to 1.0mmol/L, and the cell growth inhibition rate was detected by MTT method at 48 hours, 72 hours and 96 hours.

Reaction Conditions

0.05 mmol/L-1.0 mmol/L, 48,72 and 96 h

Applications

Ursodiol can inhibit the viability of HepG2 and BEL7402 cells. After 48 hours of Ursodiol treatment, the IC50 values of HepG2 and BEL7402 were 0.92 mmol/L and 0.86 mmol/L, respectively.
Animal experiment [2]:

Animal models

C57BL/6J wildtype mice 

Preparation Method

Five-week-old C57BL/6J WT mice (male and female) were treated with three different doses of Ursodiol (50, 150 and 450 mg/kg) for 21 days, and the mice were weighed daily during the experimental period.

Dosage form

50, 150 and 450 mg/kg/day, 21 days, i.g.

Applications

Compared with the control mice, the mice in the 50 and 450 mg/kg Ursodiol treatment groups continued to lose weight within one week of Ursodiol administration, and there was no significant difference in the body weight of the mice in the 150 mg/kg Ursodiol treatment group.

References:
[1] Liu H, Qin CY, Han GQ, Xu HW, Meng M, Yang Z. Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. World J Gastroenterol. 2007 Mar 21;13(11):1652-8.
[2] Winston JA, Rivera A, Cai J, Patterson AD, Theriot CM. Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. PLoS One. 2021 Feb 18;16(2):e0246161.

Produktdokumente (Product Documents)

Purity:>99.00%Appearance:A solid
COASDSData Sheet

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
128-13-2
Synonyme
NSC 683769, UDCA, Ursodiol
Chemischer Name
(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
SMILES
CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C
Summenformel
C24H40O4
Molekulargewicht
392.57
Löslichkeit
≥ 16mg/mL in DMSO
Lagerung
Store at 4°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Ursodiol

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%